Journal
MOLECULAR CANCER THERAPEUTICS
Volume 19, Issue 10, Pages 2139-2145Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-20-0161
Keywords
-
Categories
Funding
- NCI [P30 CA023100]
- Joan and Irwin Jacobs Fund philanthropic fund
- NIH of CTSA [TL1TR001443]
Ask authors/readers for more resources
Higher tumor mutational burden (TMB) has been correlated with response to checkpoint blockade immunotherapy. However, it is unclear whether TMB independently serves as a prognostic biomarker for outcomes in immunotherapy-naive patients. Here, we evaluated the relationship between TMB and overall survival in 1,415 immunotherapy-naive patients with diverse advanced malignancies. TMB was studied both as a tiered variable ( low <= 5 mutations/Mb, intermediate > 5 and < 20, high <= 20 and < 50, and very high <= 50) and as a continuous variable. Interestingly, we observed a parabolic correlation between TMB and overall survival, in which intermediate-range TMB correlated with decreased survival, whereas low and very high TMB correlated with improved outcomes (median survival: 238, 174, 195, and 350 weeks for low, intermediate, high, and very high TMB, respectively; multivariate P < 0.01). This corresponded to an HR of 1.29 (95% confidence interval, 1.07-1.54; P < 0.01) for intermediate-range TMB on multivariable survival analysis correcting for known confounders, including primary tumor of origin. These results demonstrate that TMB may have utility as a prognostic biomarker in immunotherapy-naive patients, with a protective effect at higher TMBs, and that studies of survival in immunotherapy-treated patients may need to stratify or randomize by TMB in a nonlinear fashion to account for this confounding.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available